Compare Becton Dickinson and Co (BDX) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Nasdaq Inc — how do they compare? Becton Dickinson and Co trades at $180.59 (market cap $49.41B), while Nasdaq Inc trades at $95.12 (market cap $53.11B). The key difference: Becton Dickinson and Co and Nasdaq Inc are close in size by market cap, and Becton Dickinson and Co pays the higher dividend (2.32%). Which is the better fit depends on your goals.
| BDX | NDAQ | |
|---|---|---|
Market Cap | $49.41B | $53.11B |
Sector | Health | Financials |
52-Week High | $185.39 | $100.98 |
52-Week Low | $138.62 | $76.85 |
Enterprise Value | $65.51B | $59.57B |
Dividend Yield | 2.32% | 1.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $179.63, up 1.57% with a bullish technical outlook supported by moving averages. The company reported strong Q3 2026 earnings, beating estimates with $3.23 EPS versus $3.14 expected, and raised full-year guidance. Revenue growth remains steady at 4.4% FX-neutral, though margins face pressure from tariffs. Analysts maintain a mixed consensus with 47% buy ratings and a $183 price target, suggesting modest upside from current levels.
The stock presents a balanced opportunity with solid fundamentals and dividend stability, but faces headwinds from margin compression and competitive pressures. Near-term catalysts include continued execution on growth initiatives, while risks include tariff impacts and healthcare regulatory changes. The current valuation at 31.39 P/E appears fair given growth prospects.
Nasdaq (NDAQ) trades at $95.62, up 1.09% today, with strong technical momentum and consistent earnings beats. Revenue grew to $8.26B in 2025, with net income margin expanding to 22.52%. The company announced the acquisition of LeveL Markets, advancing its always-on markets strategy, and maintains a bullish analyst consensus.
Outlook remains positive with a consensus price target of $109.20, offering ~14% upside. Risks include market volatility sensitivity and integration challenges from acquisitions. Solid profitability and strategic growth initiatives support a favorable investment case, though macroeconomic headwinds warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
